SCHEMBL5388290

SCHEMBL5388290

[Pd].c1ccc(P(CP(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ESR1 P03372 4/20 0.36
ESR2 Q92731 4/20 0.36
CALM1 P0DP23 1/20 0.33
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
KMT2A Q03164 1/20 0.31
TSHR P16473 2/20 0.30
IDO1 P14902 1/20 0.30
TP53 P04637 1/20 0.30
LOXL2 Q9Y4K0 1/20 0.30
TRPA1 O75762 1/20 0.30
APEX1 P27695 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4385875 1.00 CYP3A4 (0.47) CYP3A4TDP1ESR1ESR2CALM1
Hydrochloric Acid SCHEMBL10430500 0.97 CYP3A4 (0.45) CYP3A4TDP1ESR1ESR2CALM1
SCHEMBL114543 0.97 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2CALM1
SCHEMBL31175999 0.94 CYP3A4 (0.47) CYP3A4TDP1ESR1ESR2CALM1
SCHEMBL29518645 0.94 CYP3A4 (0.47) CYP3A4TDP1ESR1ESR2CALM1
SCHEMBL4998896 0.94 CYP3A4 (0.47) CYP3A4TDP1ESR1ESR2CALM1
SCHEMBL8539745 0.94 CYP3A4 (0.47) CYP3A4TDP1ESR1ESR2CALM1
SCHEMBL9661126 0.94 CYP3A4 (0.47) CYP3A4TDP1ESR1ESR2CALM1
Hydrogen Sulfide SCHEMBL28421942 0.94 TDP1 (0.47) CYP3A4TDP1ESR1ESR2CALM1
Hydrochloric Acid SCHEMBL4389637 0.91 CYP3A4 (0.45) CYP3A4TDP1ESR1ESR2CALM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186865-B2 Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture CENTRAL GLASS COMPANY, LIMITED (JP) 2007-03-06 US disclosed
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same NAT1, PNMT, AFF1 CYP3A4 145/4885TDP1 1702/4885ESR1 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.